Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2019 17:15 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
October 28, 2019 08:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Appoints Thomas J. Russo as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
October 16, 2019 07:05 ET | Source: Assembly Biosciences, Inc.

Safety and Antiviral Activity of Assembly Biosciences’ First and Second Generation Core Inhibitor Candidates In the Treatment of Chronic Hepatitis B to be Featured in a Late Breaking Session at AASLD

Phase 2a studies of ABI-H0731 + nucleos(t)ide analogs (Nrtl) in HBeAg+ patients show faster and deeper declines in HBV DNA and RNA with combination than Nrtl alone, as well as subsequent declines in...
August 09, 2019 16:30 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
August 07, 2019 08:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Announces Appointment of John McHutchison, AO, MD, as President and Chief Executive Officer

Dr. McHutchison is a world-renowned hepatologist, gastroenterologist, and anti-viral drug developerHe led the research and development of five marketed therapies for chronic hepatitis B and chronic...
August 05, 2019 16:05 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Reports Second Quarter 2019 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
June 27, 2019 07:05 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Announces First Patient Dosed with ABI-M201 in Phase 1b Clinical Trial for Mildly to Moderately Active Ulcerative Colitis

First oral microbiome biologic drug candidate from Assembly’s novel microbiome platform to enter clinical trials in patientsABI-M201 utilizes Assembly’s proprietary and patented Gemicel®...
June 25, 2019 16:05 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Announces Participation in the Microbiome Movement Drug Development Summit

SAN FRANCISCO, June 25, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus...
June 21, 2019 07:05 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Announces Presentation at International Association for the Study of the Liver Congress and Update on HBV Program in China

SAN FRANCISCO, June 21, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus...
May 09, 2019 16:05 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights

SAN FRANCISCO, May 09, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV)...